Argos Therapeutics Secures $17,500,000 Series E Financing Round

  • Feed Type
  • Date
    11/21/2013
  • Company Name
    Argos Therapeutics
  • Mailing Address
    4233 Technology Drive Durham, NC 27704 USA
  • Company Description
    Argos Therapeutics (NASDAQ: ARGS) is developing breakthrough immunotherapies that target the unique features of a patient´s disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company´s “Arcelis” technology, trains the immune system to recognize and attack the disease.
  • Website
    http://www.argostherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $17,500,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    This funding further strengthens our ability to advance our ADAPT clinical trial. In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis technology platform.
  • M&A Terms
  • Venture Investor

Trending on Xconomy